ArticleResearch and reports in tropical medicine2024
Implementation of Mass Drug Administration for Lymphatic Filariasis in Madagascar: The Progress, Effectiveness and Financial Savings of Integrating into an Existing Polio Campaign.
Article in Research and reports in tropical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Introduction: This paper presents (a) the progress made towards achieving the 2023 Lymphatic Filariasis (LF) Mass Drug Administration (MDA) campaign goals, (b) the estimated financial savings resulting from integrating LF MDA into Polio immunization campaigns, and (c) the best practices, challenges, and recommendations. Methods: In 2023, 21,336,057 people in 83 districts were affected by LF and required Preventive Chemotherapy (PC). The National NTD Control Programme (NTDCP) conducted three phases of LF MDA campaigns in those districts. In the first phase, 24 districts received triple therapy of Ivermectin, Diethylcarbamazine, and Albendazole (IDA), while the remaining 59 districts continued to receive dual therapy of Diethylcarbamazine and Albendazole (DA) as before. The first phase (15 districts) was not integrated, while the second phase (61 districts) was conducted simultaneously with the Polio Supplementary Immunization Activities (SIA) fourth round. The third phase (7 districts) was combined with periodic intensification of routine immunization (PIRI) and vitamin A supplementation. Results: In Phases 2 and 3, the campaign covered 99.97% of the targeted 12,208 villages, meaning only three villages remained untreated. In contrast, Phase 1 covered all the targeted 2,847 villages, attaining 100% geographic coverage. The 68 districts (Phase 2 and 3) that implemented an integrated approach attained an average therapeutic coverage of 76.6% (STDEV=8.3) compared to 73.2% (STDEV=6.7) among the 15 districts (Phase 1) that conducted MDA for LF without integration. The p-values for geographical and therapeutic coverage were below the significance level of 0.05, leading to the conclusion that the average geographic and therapeutic coverages for districts implementing LF MDA with and without integration into Polio immunization campaigns differed significantly. Integrating the LF MDA campaign into the Polio SIA and PIRI campaigns saved US$1,431,203. Conclusion: Incorporating LF MDA into polio immunization campaigns can improve financial efficiency and effectiveness in meeting the objectives of LF programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.